Transcriptomics

Dataset Information

0

GLP-1 directed NMDA receptor antagonism for obesity treatment [I]


ABSTRACT: The N-methyl-d-aspartate (NMDA) receptor is a glutamate-activated cation channel critical to many processes in the brain. Genome-wide association studies (GWAS) suggest that glutamatergic neurotransmission and NMDA receptor-mediated synaptic plasticity is important for body weight homeostasis1. Here, we report the engineering and preclinical development of a first-in-class bimodal molecule that integrates NMDA receptor antagonism with glucagon-like peptide-1 (GLP-1) receptor agonism to effectively reverse obesity, hyperglycemia, and dyslipidemia in rodent models of metabolic disease. We demonstrate that GLP-1-directed delivery of the NMDA receptor antagonist MK-801 affects NMDA receptor-mediated synaptic plasticity in the hypothalamus. Importantly, peptide-targeting of MK-801 specifically to GLP-1 receptor-expressing brain regions circumvent adverse physiological and behavioral effects associated with MK-801 monotherapy. In sum, our approach demonstrates the feasibility of cell specific ionotropic receptor-modulation via peptide targeting and highlights the therapeutic potential of unimolecular mixed GLP-1 receptor agonism and NMDA receptor antagonism for obesity treatment.

ORGANISM(S): Mus musculus

PROVIDER: GSE244607 | GEO | 2024/05/14

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2024-05-14 | GSE245727 | GEO
2024-04-26 | PXD045816 | Pride
2019-03-12 | GSE111708 | GEO
2024-02-06 | PXD046944 | Pride
2022-12-09 | GSE211105 | GEO
2022-10-13 | PXD014188 | Pride
2022-08-11 | PXD014149 | Pride
2020-10-01 | GSE129466 | GEO
2023-12-31 | GSE60696 | GEO
2019-12-13 | GSE108042 | GEO